The primary mission of ADiTx Therapeutics Inc. (NASDAQ:ADTX), is to enhance people’s immune systems through immune monitoring and reprogramming. However, it has been working on a new candidate AditxtScore™, reportedly for COVID-19. A validation of studies carried out by Stanford Blood Center, in Palo Alto, California, the double-multiplex assay will be used to detect antibodies against SARS-CoV-2 antigens.
The AditxtScore™ for COVID-19 has the potential to be a game-changer for the industry
In the last couple of months, the pharmaceutical industry has been put on the spot over its preparedness in the development of an urgent vaccine. This was occasioned by the fact that it was caught unawares by the presence of the COVID-19. Unfortunately, up to this day, there is no known vaccine for treating or slowing the spread of the virus.
However, as the days go by, there seems to be some hope from the horizon. Hundreds of companies have developed multiple vaccines, a majority of which are in different stages of trial and have reported positive progress. According to the CEO of Stanford Blood Center (SBC), the AditxtScore™ is one of the many hopefuls of the industry
It can be used for the simultaneous detection of various antibody isotypes such as IgM, IgA, and IgG against multiple SARS-CoV-2 antigens. All this happens in a single reaction. It is an enhanced technology against the current platform ELISA, with the capability of detecting just one antibody isotype against one antigen at a time.
Now the goal is to secure regulatory requirements to deploy AditxtScore™ quickly
Aditxt has a big vision for AditxtScore™, according to the company’s CEO and the co-founder Amro Albanna. The anticipation is that the platform will offer a different approach in the monitoring and predicting immune responses. It has demonstrated tremendous speed and accuracy; hence it is a potential candidate for addressing the ongoing COVID-19 challenge.
That said, the company has confirmed its plan for applying for an Emergency Use Authorization (EUA) and, thereafter, a 510(K) application with the FDA. Plans to begin the pilot programs are also underway, and this could take place in Q4, 2020. The strategy is to start commercializing AditxtScore in Q1, 2021.
